A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations
||Male and Female Patients
|U.S. Govt. ID:
||Gary Schwartz: 212-305-2055 / email@example.com
The purpose of this study is to learn whether IDH305 is safe and can have possible benefits for people diagnosed with glioma, cholangiocarcinoma, acute myeloid leukemia (AML), chondrosarcoma or other types of solid tumors and have IDH1R132-mutant tumors cancers that have the IDH1R132 mutation and are not getting better after treatment with currently available treatments, or who cannot tolerate currently available treatments. This study will also help to understand what IDH305 does to your body and assess what your body does to remove the drug.
This study is closed
Gary Schwartz, MD
|Have you been diagnosed with glioma, cholangiocarcinoma, acute myeloid leukemia (AML) or other types of solid tumors?